A key tariff exemption considers a drug's origin to be where its Active Pharmaceutical Ingredient (API) was made. This allows companies to manufacture an API in the US, export it for final formulation, and then re-import the finished product tariff-free, offering a significant supply chain strategy to bypass import taxes.
The current pharma tariffs are based on a "national security provision" (Section 232), which has a more secure legal footing than prior, successfully challenged tariff orders. Drawing parallels to long-standing steel and China tariffs, companies should strategize for this as a permanent feature of the trade landscape, not a temporary policy.
Effective tariff reduction requires a deep dive into three fundamental customs compliance areas: country of origin rules, correct tariff code classification, and customs valuation methods. Experts suggest the biggest savings opportunities for many firms lie in scrutinizing and optimizing these often-overlooked details to legitimately lower their dutiable base.
Unlike large firms making US investment pledges for exemptions, smaller drug makers must rely on nuanced, capital-light tactics. These include unbundling costs to lower dutiable value, using duty drawback programs for re-exported goods, and leveraging foreign trade zones to survive high tariff rates without massive infrastructure spending.